Beta Bionics (NASDAQ:BBNX) & NexGel (NASDAQ:NXGL) Head-To-Head Contrast

NexGel (NASDAQ:NXGL) and Beta Bionics (NASDAQ:BBNX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Analyst Recommendations

This is a breakdown of current ratings for NexGel and Beta Bionics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NexGel	1	2	0	0	1.67
Beta Bionics	1	4	9	1	2.67

NexGel currently has a consensus target price of $40.00, indicating a potential upside of 862.70%. Beta Bionics has a consensus target price of $23.69, indicating a potential upside of 40.36%. Given NexGel’s higher possible upside, equities analysts clearly believe NexGel is more favorable than Beta Bionics.

Earnings and Valuation

This table compares NexGel and Beta Bionics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NexGel	$12.07 million	0.17	-$3.00 million	($14.20)	-0.29
Beta Bionics	$100.25 million	9.15	-$73.20 million	($1.84)	-9.17

NexGel has higher earnings, but lower revenue than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than NexGel, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

2.2% of NexGel shares are held by institutional investors. 19.8% of NexGel shares are held by company insiders. Comparatively, 5.3% of Beta Bionics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

NexGel has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, Beta Bionics has a beta of 3.44, meaning that its share price is 244% more volatile than the S&P 500.

Profitability

This table compares NexGel and Beta Bionics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NexGel	-51.26%	-121.18%	-41.15%
Beta Bionics	-65.31%	-27.33%	-24.28%

Summary

Beta Bionics beats NexGel on 9 of the 15 factors compared between the two stocks.

About NexGel

NexGel, Inc. (NASDAQ:NXGL) develops and manufactures high-water-content hydrogel products for medical, consumer and other specialized applications. The company uses proprietary formulations and electron-beam processing to produce flexible, skin-compatible products designed to retain moisture and provide cooling, cushioning or conductive properties. Its product applications include wound care, burn and surgical care, pain management, medical diagnostics and personal wellness. NexGel supplies hydrogel sheets, patches and related components used in products such as wound dressings, therapeutic pads and medical electrodes.

About Beta Bionics

Beta Bionics, Inc. develops medical technology for people with insulin-dependent diabetes. Its main product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with less manual adjustment by users. The iLet system combines an insulin pump with dosing software that works with a continuous glucose monitor. Rather than requiring users to enter detailed insulin settings, it is initialized using the user’s body weight and adjusts insulin delivery based on glucose readings.